Evotec News - Evotec Website (English)
WEBEvotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery. Evotec SE and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery. Learn more.
Evotec reports Q1 2024 results and provides corporate update
WEBMay 22, 2024 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced financial results and corporate updates for the first quarter 2024. HIGHLIGHTS. EVOTEC’S TRANSACTIONAL BUSINESS IMPACTED BY HEADWINDS; STRONG GROWTH IN JUST – EVOTEC BIOLOGICS
Evotec SE reports H1 2024 results: Challenging year; priority reset …
WEBAug 14, 2024 — Strong progress of Just – Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been accelerated. Challenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentum.
Investor Relations & Evotec News - Evotec Website (English)
WEBNews. Sep 04, 2024. Waltham, Mass, USA. Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery. Evotec SE and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery. Learn more.
Evotec announces change in Management Board
WEBSep 3, 2024 — Evotec SE today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024. Matthias was appointed Chief Business Officer of Evotec on 01 May 2022.
Together for Medicines That Matter - Evotec Website (English)
WEBWe deploy AI and continuous manufacturing technology to allow better access to high-quality biotherapeutics. Our state-of-the-art R&D value chain, combined with highly flexible partnering business models, accelerates medicines that matter at industry-leading efficiency and cost effectiveness.
Evotec gibt Prognose Update bekannt - Evotec Website (English)
WEBAug 6, 2024 — Evotec provides guidance update. Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis. Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France.
Evotec Stock Information - Evotec Website (English)
WEBIn this section you will find detailed information regarding the Evotec SE share, such as basic share data over share price summary, stock price and charts, shareholder structure, our financial analysts and their latest recommendations, and our dividend policy.
Evotec initiates ground-breaking for new biologics facility J.POD ...
WEBSep 16, 2022 — With a modular continuous manufacturing setup, the J.POD ® technology allows for highly intensified cGMP manufacturing of biologics at flexibly scalable quantities, thus reducing both scale-up risks and manufacturing costs significantly.
Evotec and Pfizer collaborate to advance drug discovery in France
WEBEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for …